Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Roche/Genentech in race for CAR-T therapy in solid tumors

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Dec 06, 2022 12:07pm

101 Views

Post# 35153621

RE:RE:Roche/Genentech in race for CAR-T therapy in solid tumors

December 01, 2022 - Roche’s Genentech unit is walking away from a clutch of studies for its leading Alzheimer’s therapy gantenerumab weeks after the monoclonal antibody failed a pair of phase 3 studies.

https://www.fiercebiotech.com/biotech/roche-thins-alzheimers-program-after-phase-3-failure-may-seek-external-partnerships

This pull-back re-emphasizes Roche's decision to re-focus its attention on he development of Tecentriq in the treatment of various cancers to make-up for the failures that Roche has experienced in its other therapeutic areas.

<< Previous

Bullboard Posts

Next >>

QNB Metals stock adds 400 per cent after white hydrogen deal